Execution excellence

Keeping complex BioPharma deals moving and deliverable

We help you manage the messy middle of deals—where multiple functions, time zones, and counterparties need to move in sync. From advanced BD discussions through term sheet, contract, and post-signature handover, we bring structure and discipline so momentum is maintained and commitments stay realistic.

From promising discussions to signed agreements

We coordinate the work around key decision points: data sharing, diligence questions, governance proposals, and commercial scenarios. That means clear workplans, owners, and timelines across clinical, CMC, regulatory, finance, and legal—reducing the risk of surprises or last-minute re-trade.

From signed contract to operational reality

A signed deal is only the beginning. We help translate agreements into practical governance and implementation plans: who does what, when, and with which information. This makes handovers to internal project teams and alliance functions smoother and protects the value negotiated at the table.

Key areas of execution excellence

• Deal project leadership – Coordinating workstreams, timelines, and responsibilities across internal teams and external advisors.

• Diligence & workstream management – Structuring Q&A, document delivery, and decision gates so both sides stay aligned and informed.

• Preparation for key interactions – Briefing notes, decision memos, and scenario packs for partner meetings, committees, and board updates.

• Alliance & governance setup – Helping shape joint committee structures, reporting rhythms, KPIs, and escalation paths consistent with the deal.

• Post-signature handover – Packaging assumptions, commitments, and risk points so execution teams start with clarity, not ambiguity.

“A great deal on paper only creates value if it’s executed with the same discipline it was negotiated with.”

With execution excellence in place, you don’t just get deals done—you get them implemented, with clear ownership, predictable progress, and fewer unpleasant surprises for leadership, partners, and investors.